Shares of Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $2.60 and last traded at $2.65, with a volume of 549381 shares trading hands. The stock had previously closed at $2.69.
A number of research firms have commented on AUTL. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Thursday, December 5th. The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and boosted their price target for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Redburn Atlantic raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price objective on the stock in a research report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $10.40.
View Our Latest Research Report on Autolus Therapeutics
The stock's fifty day simple moving average is $3.60 and its two-hundred day simple moving average is $3.85.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the firm posted ($0.26) earnings per share. As a group, equities analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current year.
A number of hedge funds have recently bought and sold shares of AUTL. Wellington Management Group LLP raised its holdings in Autolus Therapeutics by 35.4% in the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock worth $87,919,000 after buying an additional 6,330,392 shares during the last quarter. FMR LLC raised its holdings in Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company's stock worth $64,519,000 after acquiring an additional 5,478,706 shares during the last quarter. Armistice Capital LLC lifted its position in Autolus Therapeutics by 33.8% in the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company's stock valued at $21,750,000 after acquiring an additional 1,578,000 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in Autolus Therapeutics by 27.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company's stock valued at $14,964,000 after purchasing an additional 925,000 shares during the last quarter. Finally, Great Point Partners LLC increased its holdings in shares of Autolus Therapeutics by 195.0% in the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company's stock worth $11,977,000 after purchasing an additional 2,275,000 shares in the last quarter. Institutional investors own 72.83% of the company's stock.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.